CI

At a glance

ClinicalIndex Comparison Record
Phase 1Active· 34 enrolled
Drug / intervention
Multi-peptide CMV-Modified Vaccinia Ankara Vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03560752
NCT03560752Phase 1Active
CompareCT.gov

CMV-MVA Triplex Vaccination of Stem Cell Donors to Enhance CMV Specific Immunity and Prevent CMV Viremia in Recipients After Stem Cell Transplant

City of Hope Medical Center·interventional·Posted Jun 18, 2018·Updated Dec 10, 2025

In Brief

A Phase 1 clinical trial evaluating Multi-peptide CMV-Modified Vaccinia Ankara Vaccine for Accelerated Phase CML, BCR-ABL1 Positive and 13 related conditions. Active but no longer recruiting, targeting 34 participants across 1 site.

Detailed Summary

This phase II trial studies how well multi-peptide CMV-modified vaccinia Ankara (CMV-MVA Triplex) vaccination of stem cell donors works in preventing cytomegalovirus (CMV) viremia in participants with blood cancer undergoing donor stem cell transplant. Giving a vaccine to the donors may boost the recipient's immunity to this virus and reduce the chance of CMV disease after transplant.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAccelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Phase CML, BCR-ABL1 Positive, Cytomegalovirus Positive, Donor, Hematopoietic Cell Transplant Recipient, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Myelofibrosis, Hematopoietic and Lymphoid Cell Neoplasm
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 1Active
20192020202120222023202420252026
First PostedJun 18, 2018
Enrollment StartAug 20, 2018
Primary CompletionJan 22, 2022
Study CompletionJul 29, 2026
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 8.0 years ago

Interventions

Multi-peptide CMV-Modified Vaccinia Ankara Vaccinebiological

Given via injection